Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease

There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumner, Isabelle L., Edwards, Ross A., Asuni, Ayodeji A., Teeling, Jessica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924811/
https://www.ncbi.nlm.nih.gov/pubmed/29740272
http://dx.doi.org/10.3389/fnins.2018.00254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924811/
https://www.ncbi.nlm.nih.gov/pubmed/29740272
http://dx.doi.org/10.3389/fnins.2018.00254

Ejemplares similares